Prosecution Insights
Last updated: August 15, 2026

Myriad Genetics Inc.

9 pending office actions • 6 art units • 9 examiners • 0 of 9 (0%) have an AI response strategy ready • 15 patents granted in the last 365 days

Portfolio Summary

9
Total Pending OAs
4
Non-Final OAs
4
Final Rejections
1
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

3
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (3)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

7
Hard (78%)
1
Medium (11%)
1
Easy (11%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 only1 (11%)
§101 + other5 (56%)
§102 only1 (11%)
Double-patenting only1 (11%)
Multi-statute (no §101)1 (11%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

8
Life Sciences
89% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
1
Mechanical / Eng
11% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

90 h
Manual time on pending OAs
18 h
Time saved (low, 20%)
31 h
Time saved (mid, 35%)
0.8 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
WHALEY, PABLO S 1 25.3% +21.3%
JOHANNSEN, DIANA B 1 53.3% +42.5%
HOPPE, EMMA RUTH 1 41.9% +47.0%
HORLICK, KENNETH R 1 78.9% +15.2%
HANEY, AMANDA MARIE 1 36.5% +44.5%
DAUNER, JOSEPH G 1 56.8% +35.6%
PARISI, JESSICA DANIELLE 1 77.1% +32.4%
ANDERSON-FEARS, KEENAN NEIL 1 9.1% +45.0%
PULLIAM, JOSEPH CONSTANTINE 1 37.3% +28.9%

Hard Cases (7)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.

App #TitleExaminerDue in
19088442 METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY WHALEY, PABLO S 35d overdue
17353279 METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY HANEY, AMANDA MARIE 4d overdue
18076279 METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY IN BREAST CANCER SUBTYPES HOPPE, EMMA RUTH
17678357 GENE SIGNATURES FOR CANCER PROGNOSIS HORLICK, KENNETH R
17096755 GENE SIGNATURES FOR CANCER PROGNOSIS DAUNER, JOSEPH G
17630385 METHOD FOR DETECTING GENETIC VARIATION IN HIGHLY HOMOLOGOUS SEQUENCES BY INDEPENDENT ALIGNMENT AND PAIRING OF SEQUENCE READS ANDERSON-FEARS, KEENAN NEIL
17111272 COPY NUMBER VARIANT CALLER PULLIAM, JOSEPH CONSTANTINE

Interview Candidates (9)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
19087361 METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY JOHANNSEN, DIANA B 46d overdue
19088442 METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY WHALEY, PABLO S 35d overdue
17353279 METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY HANEY, AMANDA MARIE 4d overdue
18076279 METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY IN BREAST CANCER SUBTYPES HOPPE, EMMA RUTH
17678357 GENE SIGNATURES FOR CANCER PROGNOSIS HORLICK, KENNETH R
17096755 GENE SIGNATURES FOR CANCER PROGNOSIS DAUNER, JOSEPH G
18972303 USE OF MULTI-NUCLEOTIDE AND STRUCTURAL VARIANTS FOR IMPROVED SENSITIVITY AND SPECIFICITY OF CIRCULATING TUMOR DNA ASSAYS PARISI, JESSICA DANIELLE
17630385 METHOD FOR DETECTING GENETIC VARIATION IN HIGHLY HOMOLOGOUS SEQUENCES BY INDEPENDENT ALIGNMENT AND PAIRING OF SEQUENCE READS ANDERSON-FEARS, KEENAN NEIL

Top Art Units

Art UnitApps
1682 3
1687 2
3619 1
1683 1
1681 1
1684 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
19088442 METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY WHALEY, PABLO S 3619 §103§112Other Non-Final OA 35d overdue Pending Mar 24, 2025
19087361 METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY JOHANNSEN, DIANA B 1682 DP Final Rejection 46d overdue Pending Mar 21, 2025
18076279 METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY IN BREAST CANCER SUBTYPES HOPPE, EMMA RUTH 1683 §101§103Other Final Rejection Pending Dec 06, 2022
17678357 GENE SIGNATURES FOR CANCER PROGNOSIS HORLICK, KENNETH R 1681 §101 Non-Final OA Pending Feb 23, 2022
17353279 METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY HANEY, AMANDA MARIE 1682 §101§103§112DP Final Rejection 4d overdue Pending Jun 21, 2021
17096755 GENE SIGNATURES FOR CANCER PROGNOSIS DAUNER, JOSEPH G 1682 §101§112DPOther Non-Final OA Pending Nov 12, 2020
18972303 USE OF MULTI-NUCLEOTIDE AND STRUCTURAL VARIANTS FOR IMPROVED SENSITIVITY AND SPECIFICITY OF CIRCULATING TUMOR DNA ASSAYS PARISI, JESSICA DANIELLE 1684 §102 Final Rejection Pending Dec 06, 2024
17630385 METHOD FOR DETECTING GENETIC VARIATION IN HIGHLY HOMOLOGOUS SEQUENCES BY INDEPENDENT ALIGNMENT AND PAIRING OF SEQUENCE READS ANDERSON-FEARS, KEENAN NEIL 1687 §101§102§103Other Non-Final OA Pending Jan 26, 2022
17111272 COPY NUMBER VARIANT CALLER PULLIAM, JOSEPH CONSTANTINE 1687 §101§103§112DP Non-Final OA Pending Dec 03, 2020

Managing Myriad Genetics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month